Integrating network pharmacology, metabolomics, and gut microbiota analysis to explore the effects of Jinhong tablets on chronic superficial gastritis (2503.04069v1)

Abstract: Chronic superficial gastritis (CSG) severely affects quality of life and can progress to worse gastric pathologies. Traditional Chinese Medicine (TCM) effectively treats CSG, as exemplified by Jinhong Tablets (JHT) with known anti-inflammatory properties, though their mechanism remains unclear. This study integrated network pharmacology, untargeted metabolomics, and gut microbiota analyses to investigate how JHT alleviates CSG. A rat CSG model was established and evaluated via H&E staining. We identified JHT's target profiles and constructed a multi-layer biomolecular network. Differential metabolites in plasma were determined by untargeted metabolomics, and gut microbiota diversity/composition in fecal and cecal samples was assessed via 16S rRNA sequencing. JHT markedly reduced gastric inflammation. Network pharmacology highlighted metabolic pathways, particularly lipid and nitric oxide metabolism, as essential to JHT's therapeutic effect. Metabolomics identified key differential metabolites including betaine (enhancing gut microbiota), phospholipids, and citrulline (indicating severity of CSG). Pathway enrichment supported the gut microbiota's involvement. Further microbiota analysis showed that JHT increased betaine abundance, improved short-chain fatty acid production, and elevated Faecalibaculum and Bifidobacterium, thereby alleviating gastric inflammation. In conclusion, JHT alleviates CSG via diverse metabolic processes, especially lipid and energy metabolism, and influences metabolites like betaine alongside gut microbes such as Faecalibaculum and Bifidobacterium. These findings underscore JHT's therapeutic potential and deepen our understanding of TCM's role in CSG management.